In:
Journal of Neurology, Neurosurgery & Psychiatry, BMJ, Vol. 93, No. 6 ( 2022-06), p. A27.3-A27
Abstract:
Grey matter (GM) loss is associated with cognitive decline and physical disability in multiple sclerosis (MS). In Phase 3 EXPAND study, siponimod significantly reduced disability progression, cognitive decline and whole brain volume loss in patients with secondary progressive MS (SPMS). Methods Magnetic resonance imaging (MRI) from EXPAND were pooled and analysed using high reso- lution T1 and conventional MRI. Analysis included intent-to-treat population (full analysis set, FAS) and per protocol set (PPS). Change from baseline in cortical grey matter (cGM) and thalamic volumes were assessed. Results In the FAS, adjusted mean percent change in volume from baseline at M12 and M24, respectively, was −0.07 versus −0.59 (88% reduction vs placebo, p 〈 0.0001) and −0.51 versus −0.90 (43% reduction; p 〈 0.0001) for cGM; −0.54 versus −1.01 (47% reduction; p 〈 0.0001) and −1.20 versus −1.74 (31% reduction; p=0.0001) for the thalamus. PPS values were 0.01 versus −0.60 (100% reduction; p 〈 0.0001) and −0.39 versus −1.04 (63% reduction; p 〈 0.0001) for cGM; −0.47 vs −0.94 (50% reduction; p 〈 0.0001) and −1.02 versus −1.77 (42% reduction; p 〈 0.0001) for the thalamus. Conclusions Siponimod significantly reduced cGM and thalamic volume loss compared with placebo in patients with SPMS. g.giovannoni@qmul.ac.uk
Type of Medium:
Online Resource
ISSN:
0022-3050
,
1468-330X
DOI:
10.1136/jnnp-2022-ABN.84
Language:
English
Publisher:
BMJ
Publication Date:
2022
detail.hit.zdb_id:
1480429-3
Permalink